⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL94661 | 1.00 | — | — | |
| SCHEMBL30072729 | 1.00 | — | — | |
| SCHEMBL18037713 | 0.81 | CASP1 (0.40) | — | |
| SCHEMBL16371556 | 0.81 | CASP1 (0.40) | — | |
| SCHEMBL8593221 | 0.79 | CASP1 (0.44) | — | |
| SCHEMBL9084392 | 0.79 | CASP1 (0.44) | — | |
| SCHEMBL2912701 | 0.78 | ATM (0.47) | — | |
| SCHEMBL7129224 | 0.78 | ATM (0.47) | — | |
| SCHEMBL20589645 | 0.77 | — | — | |
| SCHEMBL10335471 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 450 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4146381-B1 | SUPERPARAMAGNETIC MONODISPERSE PARTICLES AND METHOD FOR THE PRODUCTION THEREOF | N LAB TECH CENTER PTE LTD (SG) | 2026-04-08 | — | — | EP | claimed |
| CN-119593106-A | Production process of antistatic nylon fiber | 福建鑫森合纤科技有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-118767697-B | Porous membrane for asymmetric all-vanadium redox flow battery and preparation method thereof | 杭州德海艾科能源科技有限公司 | 2024-11-19 | — | — | CN | claimed |
| CN-118767697-A | Porous membrane for asymmetric all-vanadium redox flow battery and preparation method thereof | 杭州德海艾科能源科技有限公司 | 2024-10-15 | — | — | CN | claimed |
| CN-118047943-B | Cross-linkable PLGA and preparation method thereof | 山东谷雨春生物科技有限公司 | 2024-08-13 | — | — | CN | claimed |
| CN-113621112-B | Monodisperse superparamagnetic particle and preparation method thereof | N科研中心私人投资有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-118047943-A | Cross-linkable PLGA and preparation method thereof | 山东谷雨春生物科技有限公司 | 2024-05-17 | — | — | CN | claimed |
| US-20230352218-A1 | SUPERPARAMAGNETIC MONODISPERSE PARTICLES AND METHOD FOR THE PRODUCTION THEREOF | N-LAB TECHNOLOGY CENTER PTE. LTD. (SG) | 2023-11-02 | — | — | US | claimed |
| EP-4146381-A1 | SUPERPARAMAGNETIC MONODISPERSE PARTICLES AND METHOD FOR THE PRODUCTION THEREOF | N-Lab Technology Center Pte. Ltd. (SG) | 2023-03-15 | — | — | EP | claimed |
| CN-113634130-B | Pollution-resistant reverse osmosis membrane and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-11-18 | — | — | CN | claimed |
| CN-114055582-B | Preparation method of ultraviolet aging resistant wood grafted with ultraviolet absorbent | 东北林业大学 | 2022-07-01 | — | — | CN | claimed |
| US-11325912-B2 | Regio-selective synthesis of imidazo[1,2-a]pyrimidines | GENENTECH, INC. (US) | 2022-05-10 | — | — | US | claimed |
| CN-114055582-A | Preparation method of ultraviolet aging resistant wood grafted with ultraviolet absorbent | 东北林业大学 | 2022-02-18 | — | — | CN | claimed |
| CN-113634130-A | Pollution-resistant reverse osmosis membrane and preparation method and application thereof | 中国石油化工股份有限公司 | 2021-11-12 | — | — | CN | claimed |
| WO-2021225519-A1 | SUPERPARAMAGNETIC MONODISPERSE PARTICLES AND METHOD FOR THE PRODUCTION THEREOF | N-LAB TECHNOLOGY CENTER PTE. LTD. (SG) | 2021-11-11 | — | — | WO | claimed |
| CN-113621112-A | Monodisperse superparamagnetic particle and preparation method thereof | N科研中心私人投资有限公司 | 2021-11-09 | — | — | CN | claimed |
| CN-107854720-B | Medicine-carrying polyhydroxy polymer embolism microsphere with contrast function and preparation method thereof | 苏州恒瑞迦俐生生物医药科技有限公司 | 2020-12-08 | — | — | CN | claimed |
| EP-2969095-A2 | CHROMATOGRAPHY MEMBRANES STABLE UNDER CAUSTIC CONDITIONS | Natrix Separations Inc. (CA) | 2016-01-20 | — | — | EP | claimed |
| WO-2014140860-A2 | CHROMATOGRAPHY MEMBRANES STABLE UNDER CAUSTIC CONDITIONS | NATRIX SEPARATIONS INC. (CA) | 2014-09-18 | — | — | WO | claimed |
| JP-55143970-A | — | — | None | — | — | JP | disclosed |
| EP-4724427-A1 | A PROCESS OF PREPARATION OF AN ANTIBACTERIAL COMPOUND AND ITS INTERMEDIATES THEREOF | Bugworks Research, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4146381-B1 | SUPERPARAMAGNETIC MONODISPERSE PARTICLES AND METHOD FOR THE PRODUCTION THEREOF | N LAB TECH CENTER PTE LTD (SG) | 2026-04-08 | — | — | EP | disclosed |
| EP-4074800-B1 | BINDER AND PREPARATION METHOD THEREFOR, SECONDARY BATTERY, BATTERY MODULE, BATTERY PACK AND POWERED DEVICE | CONTEMPORARY AMPEREX TECHNOLOGY HONG KONG LTD (HK) | 2026-03-04 | — | — | EP | disclosed |
| EP-4688792-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4676590-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | Zoetis Services LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12496297-B1 | Compositions of autophagy modulating agents and uses thereof | WASHINGTON UNIVERSITY (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250289830-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2025-09-18 | — | — | US | disclosed |
| EP-4583874-A1 | MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES | CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) | 2025-07-16 | — | — | EP | disclosed |
| US-12351591-B2 | KRas inhibitors | ELI LILLY AND COMPANY (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250144110-A1 | COMPOSITIONS OF AUTOPHAGY MODULATING AGENTS AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2025-05-08 | — | — | US | disclosed |
| CN-119874703-A | Azatricyclic compounds and uses thereof | 杭州百新生物医药科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2025070154-A1 | POLYAMIDE RESIN, PHOTOSENSITIVE RESIN COMPOSITION, CURED PRODUCT AND METHOD FOR PRODUCING SAME, AND ELECTRONIC COMPONENT | 東レ株式会社 | 2025-04-03 | — | — | WO | disclosed |
| EP-4524135-A1 | KINESIN KIF18A INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2025-03-19 | — | — | EP | disclosed |
| US-20250084041-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | THE UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2025-03-13 | — | — | US | disclosed |
| CN-119593106-A | Production process of antistatic nylon fiber | 福建鑫森合纤科技有限公司 | 2025-03-11 | — | — | CN | disclosed |
| EP-4499233-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-3966215-B1 | SYNTHESIS OF LABELED IMIDAZO[1,2-A]PYRIMIDINES | HOFFMANN LA ROCHE (CH) | 2025-01-29 | — | — | EP | disclosed |
| CN-119212988-A | Kinesin KIF18A inhibitor and application thereof | 上海湃隆生物科技有限公司 | 2024-12-27 | — | — | CN | disclosed |
| WO-2024252423-A1 | A PROCESS OF PREPARATION OF AN ANTIBACTERIAL COMPOUND AND ITS INTERMEDIATES THEREOF | BUGWORKS RESEARCH INDIA PVT LTD (IN) | 2024-12-12 | — | — | WO | disclosed |
| CN-119095853-A | KRAS inhibitors | 伊莱利利公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-118994050-A | Dasatinib intermediate Synthesis method of intermediate | 扬州市普林斯医药科技有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118767697-B | Porous membrane for asymmetric all-vanadium redox flow battery and preparation method thereof | 杭州德海艾科能源科技有限公司 | 2024-11-19 | — | — | CN | disclosed |
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | disclosed |
| EP-4457217-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | Curza Global LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| CN-118786118-A | Antimicrobial compounds and methods | 库扎环球有限责任公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-118767697-A | Porous membrane for asymmetric all-vanadium redox flow battery and preparation method thereof | 杭州德海艾科能源科技有限公司 | 2024-10-15 | — | — | CN | disclosed |
| WO-2024206766-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2024-10-03 | — | — | WO | disclosed |
| US-20240327354-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | INSTITUT PASTEUR DE LILLE (FR) | 2024-10-03 | — | — | US | disclosed |
| US-12099297-B2 | Energy-sensitive composition, cured product, and forming method of patterned cured product | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-09-24 | — | — | US | disclosed |
| US-20240308973-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | ZOETIS SERVICES LLC | 2024-09-19 | — | — | US | disclosed |
| WO-2024191714-A1 | PHOSPHODIESTERASE 3 (PDE3) INHIBITORS | ZOETIS SERVICES LLC (US) | 2024-09-19 | — | — | WO | disclosed |
| CN-118047943-B | Cross-linkable PLGA and preparation method thereof | 山东谷雨春生物科技有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-118434727-A | Substituted pyrimidinone derivatives, pharmaceutical compositions and pharmaceutical uses thereof | 上海海雁医药科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| WO-2024132001-A1 | MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES | CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) | 2024-06-27 | — | — | WO | disclosed |
| CN-113621112-B | Monodisperse superparamagnetic particle and preparation method thereof | N科研中心私人投资有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20240199613-A1 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-06-20 | — | — | US | disclosed |
| EP-4373808-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | Institut national de la santé et de la recherche médicale (INSERM) (FR) | 2024-05-29 | — | — | EP | disclosed |
| CN-118076585-A | Gram negative bacteria efflux pump inhibitors | 国家医疗保健研究所 | 2024-05-24 | — | — | CN | disclosed |
| CN-118047943-A | Cross-linkable PLGA and preparation method thereof | 山东谷雨春生物科技有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20240158412-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | FAXIAN THERAPEUTICS, LLC | 2024-05-16 | — | — | US | disclosed |
| US-20240043451-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-02-08 | — | — | US | disclosed |
| EP-4308564-A1 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| EP-4304727-A1 | EGFR INHIBITORS | Blueprint Medicines Corporation (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20240011034-A1 | INHIBITION OF miR-29b-3p TO ENHANCE NEURONAL SURVIVAL IN HUNTINGTON'S DISEASE | WASHINGTON UNIVERSITY | 2024-01-11 | — | — | US | disclosed |
| CN-117355523-A | Polycyclic inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-05 | — | — | CN | disclosed |
| EP-4288442-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | Faxian Therapeutics, LLC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| WO-2023217230-A1 | KINESIN KIF18A INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2023-11-16 | — | — | WO | disclosed |
| US-20230352218-A1 | SUPERPARAMAGNETIC MONODISPERSE PARTICLES AND METHOD FOR THE PRODUCTION THEREOF | N-LAB TECHNOLOGY CENTER PTE. LTD. (SG) | 2023-11-02 | — | — | US | disclosed |
| WO-2023183585-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-09-28 | — | — | WO | disclosed |
| CN-114621191-B | EZH2 inhibitor and preparation and application thereof | 东南大学 | 2023-08-15 | — | — | CN | disclosed |
| EP-4221756-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023147513-A2 | COMPOSITIONS OF AUTOPHAGY MODULATING AGENTS AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023125812-A1 | SUBSTITUTED PYRIMIDONE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023129963-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2023-07-06 | — | — | WO | disclosed |
| US-11682767-B2 | Binder and preparation method thereof, secondary battery, battery module, battery pack and electrical device | CONTEMPORARY AMPEREX TECHNOLOGY CO., LIMITED (CN) | 2023-06-20 | — | — | US | disclosed |
| CN-116249554-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2023060255-A1 | QUINOLONE ALKYL AMINES AS NOVEL SEROTONIN 2A RECEPTOR (5HT2AR) AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-04-13 | — | — | WO | disclosed |
| CN-110382505-B | Heterocyclic compounds useful as antibacterial agents and process for producing the same | 巴格沃克斯研究有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4146381-A1 | SUPERPARAMAGNETIC MONODISPERSE PARTICLES AND METHOD FOR THE PRODUCTION THEREOF | N-Lab Technology Center Pte. Ltd. (SG) | 2023-03-15 | — | — | EP | disclosed |
| WO-2023002011-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-01-26 | — | — | WO | disclosed |
| EP-3634968-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | BUGWORKS RES INC (US) | 2023-01-25 | — | — | EP | disclosed |
| US-20230019732-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-01-19 | — | — | US | disclosed |
| CN-112175607-B | Organic room temperature phosphorescent material and preparation method and application thereof | 华东理工大学 | 2023-01-10 | — | — | CN | disclosed |
| CN-109988160-B | Organic compound, composition, organic optoelectronic device, and display device | 三星SDI株式会社 | 2022-12-23 | — | — | CN | disclosed |
| CN-113634130-B | Pollution-resistant reverse osmosis membrane and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-11-18 | — | — | CN | disclosed |
| US-20220359879-A1 | BINDER AND PREPARATION METHOD THEREOF, SECONDARY BATTERY, BATTERY MODULE, BATTERY PACK AND ELECTRICAL DEVICE | CONTEMPORARY AMPEREX TECHNOLOGY (HONG KONG) LIMITED (CN) | 2022-11-10 | — | — | US | disclosed |
| EP-4074800-A1 | BINDER AND PREPARATION METHOD THEREFOR, SECONDARY BATTERY, BATTERY MODULE, BATTERY PACK AND ELECTRIC DEVICE | Contemporary Amperex Technology Co., Limited (CN) | 2022-10-19 | — | — | EP | disclosed |
| WO-2022197789-A1 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022192431-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2022-09-15 | — | — | WO | disclosed |
| CN-113105475-B | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-11414386-B2 | Process for the preparation of ivacaftor and its intermediates | LAURUS LABS LIMITED (IN) | 2022-08-16 | — | — | US | disclosed |
| CN-114055582-B | Preparation method of ultraviolet aging resistant wood grafted with ultraviolet absorbent | 东北林业大学 | 2022-07-01 | — | — | CN | disclosed |
| CN-114634421-A | Preparation method of dasatinib intermediate | 济宁晟泰药业有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-114621191-A | EZH2 inhibitor and preparation and application thereof | 东南大学 | 2022-06-14 | — | — | CN | disclosed |
| US-20220146929-A1 | ENERGY-SENSITIVE COMPOSITION, CURED PRODUCT, AND FORMING METHOD OF PATTERNED CURED PRODUCT | TOKYO OHKA KOGYO CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11325912-B2 | Regio-selective synthesis of imidazo[1,2-a]pyrimidines | GENENTECH, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| CN-109796448-B | Preparation process of dasatinib | 山东罗欣药业集团股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114423763-A | Regioselective synthesis of imidazo [1,2-a ] pyrimidines | 豪夫迈·罗氏有限公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2022069520-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-04-07 | — | — | WO | disclosed |
| US-11289238-B2 | Compositions for the filling of high aspect ratio vertical interconnect access (VIA) holes | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3966216-A1 | REGIO-SELECTIVE SYNTHESIS OF IMIDAZO[1,2-A]PYRIMIDINES | F. Hoffmann-La Roche AG (CH) | 2022-03-16 | — | — | EP | disclosed |
| EP-3966215-A1 | SYNTHESIS OF LABELED IMIDAZO[1,2-A]PYRIMIDINES | F. Hoffmann-La Roche AG (CH) | 2022-03-16 | — | — | EP | disclosed |
| CN-109134458-B | Quinoline derivative and application thereof | 北京鼎材科技有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-114055582-A | Preparation method of ultraviolet aging resistant wood grafted with ultraviolet absorbent | 东北林业大学 | 2022-02-18 | — | — | CN | disclosed |
| CN-114026092-A | Synthesis of labeled imidazo [1,2-a ] pyrimidines | 豪夫迈·罗氏有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-11236080-B2 | Protein kinase inhibitors | Princeton Drug Discovery, Inc (US) | 2022-02-01 | — | — | US | disclosed |
| CN-113634130-A | Pollution-resistant reverse osmosis membrane and preparation method and application thereof | 中国石油化工股份有限公司 | 2021-11-12 | — | — | CN | disclosed |
| WO-2021225519-A1 | SUPERPARAMAGNETIC MONODISPERSE PARTICLES AND METHOD FOR THE PRODUCTION THEREOF | N-LAB TECHNOLOGY CENTER PTE. LTD. (SG) | 2021-11-11 | — | — | WO | disclosed |
| CN-113621112-A | Monodisperse superparamagnetic particle and preparation method thereof | N科研中心私人投资有限公司 | 2021-11-09 | — | — | CN | disclosed |
| US-11136330-B2 | Synthesis of labeled imidazo[1,2-A]pyrimidines | GENENTECH, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| CN-108473487-B | Protein kinase inhibitor | 普林斯顿药物研发公司 | 2021-08-03 | — | — | CN | disclosed |
| CN-113105475-A | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2021-07-13 | — | — | CN | disclosed |
| US-20210174983-A1 | COMPOSITIONS FOR THE FILLING OF HIGH ASPECT RATIO VERTICAL INTERCONNECT ACCESS (VIA) HOLES | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC | 2021-06-10 | — | — | US | disclosed |
| CN-110483496-B | Derivative with uracil-benzothiazole structure, preparation method thereof and application of anti-HCV (hepatitis C virus) medicament | 杭州市西溪医院 | 2021-05-04 | — | — | CN | disclosed |
| CN-108727366-B | Benzophenanthroline derivatives and application thereof | 北京鼎材科技有限公司 | 2021-04-30 | — | — | CN | disclosed |
| US-10912780-B2 | Heterocyclic compounds useful as anti-bacterial agents and method for production thereof | Bugworks Research, Inc. (US) | 2021-02-09 | — | — | US | disclosed |
| CN-112175607-A | Organic room temperature phosphorescent material and preparation method and application thereof | 华东理工大学 | 2021-01-05 | — | — | CN | disclosed |
| CN-109503511-B | Preparation method of dasatinib intermediate | 山东罗欣药业集团股份有限公司 | 2021-01-01 | — | — | CN | disclosed |
| US-20200407323-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR AND ITS ITERMEDIATES | LAURUS LABS LIMITED (IN) | 2020-12-31 | — | — | US | disclosed |
| CN-107854720-B | Medicine-carrying polyhydroxy polymer embolism microsphere with contrast function and preparation method thereof | 苏州恒瑞迦俐生生物医药科技有限公司 | 2020-12-08 | — | — | CN | disclosed |
| US-20200369670-A1 | REGIO-SELECTIVE SYNTHESIS OF IMIDAZO[1,2-a]PYRIMIDINES | GENENTECH, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200354369-A1 | SYNTHESIS OF LABELED IMIDAZO[1,2-A]PYRIMIDINES | GENENTECH, INC. (US) | 2020-11-12 | — | — | US | disclosed |
| WO-2020227575-A1 | SYNTHESIS OF LABELED IMIDAZO[1,2-A]PYRIMIDINES | GENENTECH, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020227576-A1 | REGIO-SELECTIVE SYNTHESIS OF IMIDAZO[1,2-A]PYRIMIDINES | GENENTECH, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| US-10822348-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-03 | — | — | US | disclosed |
| EP-3344249-B1 | PROCESSES FOR THE PREPARATION OF IVACAFTOR | LAURUS LABS LTD (IN) | 2020-10-28 | — | — | EP | disclosed |
| US-10815202-B2 | Process for the preparation of ivacaftor | LAURUS LABS LIMITED (IN) | 2020-10-27 | — | — | US | disclosed |
| EP-2841429-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2020-10-21 | — | — | EP | disclosed |
| US-10800792-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-13 | — | — | US | disclosed |
| CN-109678853-B | Preparation process of dasatinib | 山东罗欣药业集团股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-109265455-B | Preparation method of dasatinib | 新发药业有限公司 | 2020-08-18 | — | — | CN | disclosed |
| CN-109503568-B | Preparation method of dasatinib | 山东罗欣药业集团股份有限公司 | 2020-08-07 | — | — | CN | disclosed |
| CN-109369638-B | Preparation process of dasatinib | 山东罗欣药业集团股份有限公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378156-A | Force-induced responsive polymer with light-operated switch function | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| US-10689396-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-23 | — | — | US | disclosed |
| US-20200123148-A1 | PROTEIN KINASE INHIBITORS | PRINCETON DRUG DISCOVERY INC (US) | 2020-04-23 | — | — | US | disclosed |
| EP-3634968-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | Bugworks Research, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20200085834-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | Bugworks Research, Inc. | 2020-03-19 | — | — | US | disclosed |
| WO-2020055192-A2 | PREPARATION METHOD FOR QUINOLINE-5, 8-DIONE DERIVATIVE WHICH IS TGASE 2 INHIBITOR | 재단법인 대구경북첨단의료산업진흥재단 | 2020-03-19 | — | — | WO | disclosed |
| US-10590118-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2020-03-17 | — | — | US | disclosed |
| US-10556897-B2 | Protein kinase inhibitors | Princeton Drug Discovery, Inc (US) | 2020-02-11 | — | — | US | disclosed |
| US-10479786-B2 | Protein kinase inhibitors | Princeton Drug Discovery, Inc (US) | 2019-11-19 | — | — | US | disclosed |
| US-20190345111-A1 | PROCESS FOR THE PREPARATION OF IVACAFTOR | Laurus Labs Ltd. (IN) | 2019-11-14 | — | — | US | disclosed |
| EP-3555092-A1 | PROTEIN KINASE INHIBITORS | Princeton Drug Discovery Inc (US) | 2019-10-23 | — | — | EP | disclosed |
| US-10428083-B2 | Heterocyclylmethyl-thienouracile as antagonists of the adenosine-A2B-receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-01 | — | — | US | disclosed |
| US-20190284204-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-19 | — | — | US | disclosed |
| US-20190284203-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-19 | — | — | US | disclosed |
| EP-3515919-A1 | N3-CYCLICALLY SUBSTITUTED THIENOURACILES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-10301302-B2 | Crystalline forms of N-(2-chloro-6-methy]phenvn-2-[F6-[4-(2-hvdroxvethvl)-L-piperazin-vil-2-methvil-4-pvrimidinvllaminol-5-thiazolecarboxamide and their process thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2019-05-28 | — | — | US | disclosed |
| EP-3029038-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2019-03-27 | — | — | EP | disclosed |
| US-20190071437-A1 | PROTEIN KINASE INHIBITORS | PRINCETON DRUG DISCOVERY INC (US) | 2019-03-07 | — | — | US | disclosed |
| US-10174018-B2 | Protein kinase inhibitors | PRINCETON DRUG DISCOVERY INC (US) | 2019-01-08 | — | — | US | disclosed |
| EP-3274352-B1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | Bayer Pharma AG (DE) | 2019-01-02 | — | — | EP | disclosed |
| US-10160726-B2 | Quinolone derivatives as antibacterials | NOVARTIS AG (CH) | 2018-12-25 | — | — | US | disclosed |
| WO-2018225097-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | BUGWORKS RESEARCH INDIA PVT LTD (IN) | 2018-12-13 | — | — | WO | disclosed |
| US-20180339982-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-11-29 | — | — | US | disclosed |
| US-20180312496-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORP (FI) | 2018-11-01 | — | — | US | disclosed |
| EP-2923703-B1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIO INC (US) | 2018-09-19 | — | — | EP | disclosed |
| US-10077259-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2018-09-18 | — | — | US | disclosed |
| US-20180244622-A1 | PROCESSES FOR THE PREPARATION OF IVACAFTOR | Laurus Labs Ltd. (IN) | 2018-08-30 | — | — | US | disclosed |
| EP-3344249-A1 | PROCESSES FOR THE PREPARATION OF IVACAFTOR | Laurus Labs Private Limited (IN) | 2018-07-11 | — | — | EP | disclosed |
| EP-3092227-B1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORP (FI) | 2018-07-11 | — | — | EP | disclosed |
| US-20180186784-A1 | CRYSTALLINE FORMS OF N-(2-CHLORO-6-METHY]PHENVN-2-[F6-[4-(2-HVDROXVETHVL)-L-PIPERAZIN-VIL-2-METHVIL-4-PVRIMIDINVLLAMINOL-5-THIAZOLECARBOXAMIDE AND THEIR PROCESS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-07-05 | — | — | US | disclosed |
| WO-2018111893-A1 | PROTEIN KINASE INHIBITORS | PRINCETON DRUG DISCOVERY INC (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018103058-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | WO | disclosed |
| EP-3317266-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | Orion Corporation (FI) | 2018-05-09 | — | — | EP | disclosed |
| US-20180117043-A1 | USE OF SRC PROTEIN INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF ALZHEIMER'S DISEASE | JENKEM TECHNOLOGY CO., LTD. (BEIJING) (CN) | 2018-05-03 | — | — | US | disclosed |
| US-20180099961-A1 | PROTEIN KINASE INHIBITORS | PRINCETON DRUG DISCOVERY INC (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099959-A1 | PROTEIN KINASE INHIBITORS | PRINCETON DRUG DISCOVERY INC (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099960-A1 | PROTEIN KINASE INHIBITORS | PRINCETON DRUG DISCOVERY INC (US) | 2018-04-12 | — | — | US | disclosed |
| WO-2018054846-A1 | N3-CYCLICALLY SUBSTITUTED THIENOURACILES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2018-03-29 | — | — | WO | disclosed |
| EP-2291358-B1 | GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME (US) | 2018-03-28 | — | — | EP | disclosed |
| US-20180065981-A1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-08 | — | — | US | disclosed |
| EP-3274352-A1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | Bayer Pharma Aktiengesellschaft (DE) | 2018-01-31 | — | — | EP | disclosed |
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2017-10-12 | — | — | US | disclosed |
| US-9781933-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-10 | — | — | US | disclosed |
| US-9783509-B2 | Six-membered C-N-linked aryl sulfide derivatives and aryl sulfoxide derivatives as pest conrol agents | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-10-10 | — | — | US | disclosed |
| US-20170283431-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-05 | — | — | US | disclosed |
| US-20170217897-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | WUXI APPTEC (CN) | 2017-08-03 | — | — | US | disclosed |
| EP-3189037-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL Business PLC (GB) | 2017-07-12 | — | — | EP | disclosed |
| EP-3177593-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | Novartis AG (CH) | 2017-06-14 | — | — | EP | disclosed |
| WO-2017037672-A1 | PROCESSES FOR THE PREPARATION OF IVACAFTOR | LAURUS LABS PRIVATE LIMITED (IN) | 2017-03-09 | — | — | WO | disclosed |
| US-9565856-B2 | Tetrazolinone compounds and its use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-14 | — | — | US | disclosed |
| WO-2017002131-A1 | CRYSTALLINE FORMS OF N-(2-CHLORO-6-METHY]PHENVN-2-[F6-[4-(2-HVDROXVETHVL)-L- PIPERAZINVIL-2-METHVL-4-PVRIMIDINVLLAMINOL-5-THIAZOLECARBOXAMIDE AND THEIR PROCESS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-01-05 | — | — | WO | disclosed |
| WO-2017001733-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2017-01-05 | — | — | WO | disclosed |
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | disclosed |
| EP-3092227-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-11-16 | — | — | EP | disclosed |
| US-20160315265-A1 | 4,7-PHENANTHROLINE CONTAINING POLYMER AND ORGANIC ELECTRONIC DEVICE | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2016-10-27 | — | — | US | disclosed |
| WO-2016150901-A1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-29 | — | — | WO | disclosed |
| US-20160251321-A1 | SIX-MEMBERED C-N-LINKED ARYL SULFIDE DERIVATIVES AND ARYL SULFOXIDE ERIVATVES AS PEST CONROL AGENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-09-01 | — | — | US | disclosed |
| US-20160174558-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-23 | — | — | US | disclosed |
| US-9365526-B2 | Process for the preparation of dasatinib and its intermediates | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-06-14 | — | — | US | disclosed |
| EP-3029038-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | Sumitomo Chemical Company Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
| EP-3019481-A1 | SIX-MEMBERED C-N-LINKED ARYL SULFIDE DERIVATIVES AND ARYL SULFOXIDE DERIVATIVES AS PEST CONTROL AGENTS | Bayer CropScience Aktiengesellschaft (DE) | 2016-05-18 | — | — | EP | disclosed |
| WO-2016034512-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016020836-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | NOVARTIS AG (CH) | 2016-02-11 | — | — | WO | disclosed |
| EP-2969095-A2 | CHROMATOGRAPHY MEMBRANES STABLE UNDER CAUSTIC CONDITIONS | Natrix Separations Inc. (CA) | 2016-01-20 | — | — | EP | disclosed |
| US-20150336913-A1 | PROCESS FOR THE PREPARATION OF DASATINIB AND ITS INTERMEDIATES | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2015-11-26 | — | — | US | disclosed |
| EP-2923703-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | Abraxis BioScience, Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2015104653-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015082879-A1 | 4,7-PHENANTHROLINE CONTAINING POLYMER AND ORGANIC ELECTRONIC DEVICE | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2015-06-11 | — | — | WO | disclosed |
| EP-2346830-B1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME (US) | 2015-05-13 | — | — | EP | disclosed |
| EP-2425840-B1 | Triazine derivatives and their therapeutical applications | ABRAXIS BIOSCIENCE INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2841429-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | Sumitomo Chemical Company Limited (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20150051171-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
| WO-2015004028-A1 | SIX-MEMBERED C-N-LINKED ARYL SULFIDE DERIVATIVES AND ARYL SULFOXIDE DERIVATIVES AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AG (DE) | 2015-01-15 | — | — | WO | disclosed |
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140273158-A1 | Chromatography Membranes Stable Under Caustic Conditions | NATRIX SEPARATIONS INC. (CA) | 2014-09-18 | — | — | US | disclosed |
| WO-2014140860-A2 | CHROMATOGRAPHY MEMBRANES STABLE UNDER CAUSTIC CONDITIONS | NATRIX SEPARATIONS INC. (CA) | 2014-09-18 | — | — | WO | disclosed |
| US-8778957-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-07-15 | — | — | US | disclosed |
| WO-2014102759-A2 | PROCESS FOR THE PREPARATION OF DASATINIB AND ITS INTERMEDIATES | RANBAXY LABORATORIES LIMITED (IN) | 2014-07-03 | — | — | WO | disclosed |
| US-20140179711-A1 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-26 | — | — | US | disclosed |
| US-8680103-B2 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| US-8633208-B2 | 6-1H-imidazo-quinazoline and quinolines derivatives, new MAO inhibitors and imidazoline receptor ligands | ROTTAPHARM S.P.A (IT) | 2014-01-21 | — | — | US | disclosed |
| US-8623818-B2 | Glucagon receptor antagonists, compositions, and methods for their use | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8580786-B2 | Triazine derivatives and their therapeutical applications | NANT HOLDINGS IP, LLC (US) | 2013-11-12 | — | — | US | disclosed |
| WO-2013162072-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-10-31 | — | — | WO | disclosed |
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| EP-2473491-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| EP-1711481-B2 | CRYSTALLINE MONOHYDRATE AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8436015-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2257551-B1 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-10 | — | — | EP | disclosed |
| US-8349828-B2 | Azatricyclic antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-01-08 | — | — | US | disclosed |
| EP-2315588-B1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | ROTTAPHARM SPA (IT) | 2012-12-19 | — | — | EP | disclosed |
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20120302750-A1 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-29 | — | — | US | disclosed |
| US-20120270864-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE-DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB | 2012-10-25 | — | — | US | disclosed |
| EP-1951228-B1 | BICYCLIC SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-1951042-B1 | SPIROLACTAM TRICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-1954135-B1 | SPIROLACTAM ARYL CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-1951051-B1 | SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-10-03 | — | — | EP | disclosed |
| EP-1954268-B1 | SPIROLACTAM BICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20120238576-A1 | Triazine Derivatives and their Therapeutical Applications | CALIFORNIA CAPITAL EQUITY, LLC (CA) | 2012-09-20 | — | — | US | disclosed |
| CN-102675202-A | Preparation method of amino-substituted 2(1H)-quinolinone compounds | Chizhou fangda science and technology co ltd | 2012-09-19 | — | — | CN | disclosed |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| US-8242270-B2 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-14 | — | — | US | disclosed |
| EP-2473491-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| EP-2468743-A1 | Nitrogen-containing bicyclic compounds useful as antibacterial agents | Toyama Chemical Co., Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
| CN-101611038-B | 2-quinolinone and 2-quinoxalinone-derivatives and their use as antibacterial agents | ASTRAZENECA AB | 2012-06-13 | — | — | CN | disclosed |
| US-8183379-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2440050-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | Abraxis BioScience, LLC (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| EP-2425840-A1 | Triazine derivatives and their therapeutical applications | Abraxis BioScience, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20120010193-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-01-12 | — | — | US | disclosed |
| US-8071770-B2 | Spirohydantoin aryl CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071771-B2 | Bicyclic spirohydantoin CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071772-B2 | Spirolactam bicyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2011112731-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| EP-2346830-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck Sharp & Dohme Corp. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20110172256-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2011-07-14 | — | — | US | disclosed |
| US-7968540-B2 | Spirohydantoin tricyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20110150763-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-7947677-B2 | Spirolactam tricyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110118289-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | ROTTAPHARM S.P.A. (IT) | 2011-05-19 | — | — | US | disclosed |
| EP-2315588-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | Rottapharm S.p.A. (IT) | 2011-05-04 | — | — | EP | disclosed |
| US-20110065634-A1 | GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
| EP-2291358-A1 | GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | Schering Corporation (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2011025565-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2011-03-03 | — | — | WO | disclosed |
| US-20100331318-A1 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-12-30 | — | — | US | disclosed |
| EP-1951251-B1 | SPIROHYDANTOIN ARYL CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7858782-B2 | Triazine derivatives and their therapeutical applications | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-28 | — | — | US | disclosed |
| WO-2010144338-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
| US-7851464-B2 | Spirolactam aryl CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-12-14 | — | — | US | disclosed |
| EP-2136807-B1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LTD (GB) | 2010-11-03 | — | — | EP | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100144717-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE-DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100137353-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-7728007-B2 | Therapeutic amides | WAYNE STATE UNIVERSITY (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1305296-B9 | 5-SUBSTITUTED PYRIMIDINE DERIVATIVES OF CONFORMATIONALLY LOCKED NUCLEOSIDE ANALOGUES | US GOV HEALTH & HUMAN SERV (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2010030722-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| EP-1954697-B1 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-02-24 | — | — | EP | disclosed |
| US-20090325991-A1 | Spirolactam Bicyclic CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-12-31 | — | — | US | disclosed |
| EP-1711481-B1 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-12-30 | — | — | EP | disclosed |
| EP-2136807-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| CN-101611038-A | 2-quinolinone and 2-quinoxalinone-derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | CN | disclosed |
| WO-2009152868-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | ROTTAPHARM S.P.A. (IT) | 2009-12-23 | — | — | WO | disclosed |
| EP-2120964-A2 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | Abraxis BioScience, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-2121702-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE- DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009140342-A1 | GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | SCHERING CORPORATION (US) | 2009-11-19 | — | — | WO | disclosed |
| US-20090281080-A1 | Spirohydantoin Tricyclic CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-11-12 | — | — | US | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090247514-A1 | Spirolactam aryl cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2009-10-01 | — | — | US | disclosed |
| US-20090239870-A1 | Spirohydantoin Aryl Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| EP-1305296-B1 | 5-SUBSTITUTED PYRIMIDINE DERIVATIVES OF CONFORMATIONALLY LOCKED NUCLEOSIDE ANALOGUES | US GOV HEALTH & HUMAN SERV (US) | 2009-09-09 | — | — | EP | disclosed |
| US-7585863-B2 | Antitumor agents; such as (2-(4-(7-Chloro-2-quinoxalinyl)oxy)propionylamino ethansulfonic acid; {2-{4-(7-Chloro-quinoxalin-2-yloxy)-phenoxy}propionyl amino}acetic acid | WAYNE STATE UNIVERSITY (US) | 2009-09-08 | — | — | US | disclosed |
| US-20090176757-A1 | Bicyclic Spirohydantoin CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-07-09 | — | — | US | disclosed |
| US-20090149650-A1 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-06-11 | — | — | US | disclosed |
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090105219-A1 | Spirolactam Tricyclic CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-04-23 | — | — | US | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| EP-2044077-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | Glaxo Group Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| US-7507749-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2009-03-24 | — | — | US | disclosed |
| US-20090076073-A1 | THERAPEUTIC AMIDES | WAYNE STATE UNIVERSITY | 2009-03-19 | — | — | US | disclosed |
| US-20090069372-A1 | ANTITUMOR AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-12 | — | — | US | disclosed |
| US-7491725-B2 | purification of crystalline N-(2-chloro-6-methylphenyl)-2-(6-(4-(3-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (IV) using ethanol/water mixture; high efficiency, high yield process to get 2-aminothiazole-5-carboxamides using halogention reaction; by-products inhibition | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090018133-A1 | Novel Adamantane Derivatives | FORD RHONAN | 2009-01-15 | — | — | US | disclosed |
| WO-2009001126-A1 | SUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS ANTIBATERIAL AGENTS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009002955-A1 | PROCESS FOR THE PREPARATION OF (2R)-2-[4-(7-BROMO-2-QUINOLYLOXY)PHENOXY]PROPANOIC ACID | SANOFI-AVENTIS U.S. LLC (US) | 2008-12-31 | — | — | WO | disclosed |
| US-7470788-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
| US-20080280892-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| WO-2008125594-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
| EP-1980251-A1 | Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008120003-A1 | SUBSTITUTED PIPERIDINES FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | WO | disclosed |
| US-20080221110-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
| US-20080214455-A1 | Novel Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| EP-1954135-A2 | SPIROLACTAM ARYL CGRP RECEPTOR ANTAGONISTS | Merck and Co., Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1954268-A2 | SPIROLACTAM BICYCLIC CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7408067-B2 | Aza-cyclic compounds as modulators of acetylcholine receptors | MERCK + CO., INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20080176853-A1 | e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders | ABRAXIS BIOSCIENCE, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| EP-1940794-A2 | QUINOLINE DERIVATIVES AND USE AS ANTITUMOR AGENTS | WAYNE STATE UNIVERSITY (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2008076883-A2 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008071961-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE- DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | WO | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
| WO-2008009700-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| US-20070232643-A1 | Quinoline derivative, e.g. 2[4-(7-chloroquinolin-2-yloxy)phenoxy]propionic acid sodium salt; anticarcinogenic, antitumor agent; colon, breast, melanoma, pancreatic cancer or adenocarcinoma; melanoma, or leukemia; based on herbicides | WAYNE STATE UNIVERSITY | 2007-10-04 | — | — | US | disclosed |
| EP-1439841-B1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO INC (US) | 2007-09-19 | — | — | EP | disclosed |
| US-7241894-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241893-B2 | Thiazolinone 2-substituted quinolines | HOFFMAN-LA ROCHE INC. (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1791836-A1 | THIAZOLINONE 2-SUBSTITUTED QUINOLINES | F. Hoffmann-Roche AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| WO-2007061696-A2 | SPIROLACTAM BICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061677-A2 | SPIROLACTAM ARYL CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007059330-A2 | CUBANE NUCLEOSIDE ANALOGS | MEDKURA INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-7196076-B2 | Androgen receptor modulators and methods of use thereof | MERCK & CO., INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070060612-A1 | Antitumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-03-15 | — | — | US | disclosed |
| WO-2007030780-A2 | QUINOLINE DERIVATIVES AND USE AS ANTITUMOR AGENTS | WAYNE STATE UNIVERSITY (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070054938-A1 | Antitumor agents | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-03-08 | — | — | US | disclosed |
| US-20070054912-A1 | Modulators of acetylcholine receptors | ASTLES PETER C | 2007-03-08 | — | — | US | disclosed |
| US-20060293333-A1 | Antitumor agents; such as (2-(4-(7-Chloro-2-quinoxalinyl)oxy)propionylamino ethansulfonic acid; {2-{4-(7-Chloro-quinoxalin-2-yloxy)-phenoxy}propionyl amino}acetic acid | WAYNE STATE UNIVERSITY | 2006-12-28 | — | — | US | disclosed |
| US-7148236-B2 | Modulators of acetylcholine receptors | MERCK & CO., INC. (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1711481-A2 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-10-18 | — | — | EP | disclosed |
| US-7109341-B2 | Therapeutic amides | WAYNE STATE UNIVERSITY (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2006029863-A1 | THIAZOLINONE 2-SUBSTITUTED QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |
| US-20060063804-A1 | Thiazolinone 2-substituted quinolines | CHEN LI | 2006-03-23 | — | — | US | disclosed |
| US-7009050-B2 | 5-Substituted pyrimidine derivatives of conformationally locked nucleoside analogues | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-03-07 | — | — | US | disclosed |
| US-20060004067-A1 | N-(2-chloro-6-methylphenyl)-2-(6-(4-(3-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide; high efficiency, high yield process to get 2-aminothiazole-5-carboxamides using halogention reaction; by-products inhibition; anticancer, psoriasis | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| US-20050282837-A1 | 5-SUBSTITUTED PYRIMIDINE DERIVATIVES OF CONFORMATIONALLY LOCKED NUCLEOSIDE ANALOGUES | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE | 2005-12-22 | — | — | US | disclosed |
| EP-1439841-A4 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050215795-A1 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-29 | — | — | US | disclosed |
| WO-2005077945-A2 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050182088-A1 | Modulators of acetylcholine receptors | MERCK SHARP & DOHME CORP. | 2005-08-18 | — | — | US | disclosed |
| US-20050159447-A1 | Antitumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-21 | — | — | US | disclosed |
| EP-1539699-A1 | 4- 7'-HALO-2-QUINO (XA-) LINYLOXY!PHENOXY-PROPIONIC ACID DERIVATIVES AS ANTINEOPLASTIC AGENTS | WAYNE STATE UNIVERSITY (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050090524-A1 | Novel adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-28 | — | — | US | disclosed |
| US-20050070520-A1 | Aza-cyclic compounds as modulators of acetylcholine receptors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| US-6867219-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1412332-B1 | QUINOLINE DERIVATIVES AND USE THEREOF AS ANTITUMOR AGENTS | UNIV WAYNE STATE (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1490341-A1 | NOVEL ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2004-12-29 | — | — | EP | disclosed |
| US-6821967-B2 | AMINES SUCH AS 9-(4-(4-(BENZOTHIAZOL-2-YL)-PIPERAZIN-1-YL)-BUTYL)-9H-FLUORENE-9-CARBOXYLIC ACID (2,2,2-TRIFLUOROETHYL) AMIDE, USED AS MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN ANTAGONISTS, TO PREVENT ATHEROSCLEROSIS OR HYPERLIPEMIA | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-11-23 | — | — | US | disclosed |
| EP-1472248-A1 | MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-11-03 | — | — | EP | disclosed |
| EP-1467986-A1 | AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040198717-A1 | Androgen receptor modulators and methods of use thereof | MERCK SHARP & DOHME CORP. | 2004-10-07 | — | — | US | disclosed |
| EP-1439841-A2 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | Merck & Co., Inc. (US) | 2004-07-28 | — | — | EP | disclosed |
| US-20040132618-A1 | Therapeutic amides | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-07-08 | — | — | US | disclosed |
| EP-1412332-A1 | QUINOLINE DERIVATIVES AND USE THEREOF AS ANTITUMOR AGENTS | WAYNE STATE UNIVERSITY (US) | 2004-04-28 | — | — | EP | disclosed |
| WO-2004004651-A2 | THERAPEUTIC AMIDES | WAYNE STATE UNIVERSITY (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004005260-A1 | A-`7-HALO-2-QUINO (XA-) LINYLOXY!PHENOXY-PROPIONIC ACID DERIVATIVES AS ANTINEOPLASTIC AGENTS | WAYNE STATE UNIVERSITY (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003080579-A1 | NOVEL ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | WO | disclosed |
| EP-1131299-B1 | METHOD FOR PRODUCING 1-SUBSTITUTED 5- OR 3-HYDROXYPYRAZOLES | BASF AG (DE) | 2003-09-17 | — | — | EP | disclosed |
| US-20030166637-A1 | Substituted piperazine derivatives, the preparation thereofand their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-09-04 | — | — | US | disclosed |
| EP-1131298-B1 | METHOD FOR THE PRODUCTION OF 1-SUBSTITUTED 5-HYDROXYPYRAZOLES | BASF AG (DE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003062235-A1 | MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003062224-A1 | AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
| US-20030144321-A1 | Antitumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-31 | — | — | US | disclosed |
| EP-1305296-A2 | 5-SUBSTITUTED PYRIMIDINE DERIVATIVES OF CONFORMATIONALLY LOCKED NUCLEOSIDE ANALOGUES | The Government of the United States of America, as represented by the Secretary Department of Health and Human Services (US) | 2003-05-02 | — | — | EP | disclosed |
| WO-2003034987-A2 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003011832-A1 | QUINOLINE DERIVATIVES AND USE THEREOF AS ANTITUMOR AGENTS | WAYNE STATE UNIVERSITY (US) | 2003-02-13 | — | — | WO | disclosed |
| EP-1255736-A2 | SUBSTITUTED PIPERAZINE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) | Boehringer Ingelheim Pharma KG (DE) | 2002-11-13 | — | — | EP | disclosed |
| US-6392058-B1 | REACTING AN ALKYL VINYL ETHER WITH PHOSGENE; FORMING ACYL CHLORIDE; ESTERIFICATION; REACTING WITH HYDRAZINE | BASF AKTIENGESELLSCHAFT (DE) | 2002-05-21 | — | — | US | disclosed |
| EP-0867477-B1 | Polycyclic compounds | CIBA SC HOLDING AG (CH) | 2002-05-02 | — | — | EP | disclosed |
| EP-0911333-B1 | Pyrazolo[4,3-d]pyrimidine derivatives and pharmaceutical compositions containing them | PFIZER (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2002008204-A2 | 5-SUBSTITUTED PYRIMIDINE DERIVATIVES OF CONFORMATIONALLY LOCKED NUCLEOSIDE ANALOGUES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-01-31 | — | — | WO | disclosed |
| US-6329530-B1 | REACTING ALKYL VINYL ETHER WITH PHOSGENE OR PHOSGENE DERIVATIVE TO FORM ACYL CHLORIDE DERIVATIVE; DEHYDROCHLORIANTING TO FORM 3-ALKOXYACRYLOYL CHLORIDE COMPOUND; REACTING WITH ALKYLHYDRAZINE | BASF AKTIENGESELLSCHAFT (DE) | 2001-12-11 | — | — | US | disclosed |
| EP-1131298-A2 | METHOD FOR THE PRODUCTION OF 1-SUBSTITUTED 5-HYDROXYPYRAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2001-09-12 | — | — | EP | disclosed |
| EP-1131299-A2 | METHOD FOR PRODUCING 1-SUBSTITUTED 5- OR 3-HYDROXYPYRAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2001-09-12 | — | — | EP | disclosed |
| WO-2001047898-A2 | SUBSTITUTED PIPERAZINE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-07-05 | — | — | WO | disclosed |
| US-6235742-B1 | CARDIOVASCULAR DISORDERS; ANTIALLERGENS | PFIZER INC. | 2001-05-22 | — | — | US | disclosed |
| US-6090805-A | Tocolytic oxytocin receptor antagonists | MERCK & CO., INC. (US) | 2000-07-18 | — | — | US | disclosed |
| WO-2000031042-A2 | METHOD FOR PRODUCING 1-SUBSTITUTED 5- OR 3-HYDROXYPYRAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000031041-A2 | METHOD FOR THE PRODUCTION OF 1-SUBSTITUTED 5-HYDROXYPYRAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2000-06-02 | — | — | WO | disclosed |
| EP-0977743-A1 | PROTEASE INHIBITORS | Smithkline Beecham (US) | 2000-02-09 | — | — | EP | disclosed |
| US-5968252-A | PYRIDO-(2,3-G)-QUINOLINE-DIONE DERIVATIVES; PIGMENTS FOR AUTOMOBILE PAINTS AND COATINGS | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0911333-A1 | Pyrazolo[4,3-d]pyrimidine derivatives and pharmaceutical compositions containing them | PFIZER INC. (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1998049152-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
| EP-0867477-A1 | Polycyclic compounds | Ciba SC Holding AG (CH) | 1998-09-30 | — | — | EP | disclosed |
| EP-0805681-A4 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0587072-B1 | Process for the preparation of alpha, beta-unsaturated beta-oxycarboxylic acid chlorides | BASF AG (DE) | 1998-01-07 | — | — | EP | disclosed |
| US-5703224-A | Antiviral c-nucleoside derivatives | NIPPON SHINYAKU CO. LTD. (JP) | 1997-12-30 | — | — | US | disclosed |
| EP-0805681-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1997-11-12 | — | — | EP | disclosed |
| US-5652247-A | VASOPRESSIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 1997-07-29 | — | — | US | disclosed |
| EP-0733630-A1 | NUCLEOSIDE DERIVATIVE | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1996-09-25 | — | — | EP | disclosed |
| US-5543568-A | Preparation of α,β-unsaturated β-oxycarboxylic acid chlorides | BASF AKTIENGESELLSCHAFT (DE) | 1996-08-06 | — | — | US | disclosed |
| EP-0317188-B1 | Heteroaromatic enamide derivatives and their use as pesticides | ROUSSEL UCLAF (FR) | 1995-09-27 | — | — | EP | disclosed |
| US-5436254-A | Vaopressin antagonists | OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| US-RE34722-E | Antiulcer agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-06 | — | — | US | disclosed |
| EP-0382185-B1 | Carbostyril derivatives | OTSUKA PHARMA CO LTD (JP) | 1994-06-15 | — | — | EP | disclosed |
| EP-0587072-A1 | Process for the preparation of alpha, beta-unsaturated beta-oxycarboxylic acid chlorides | BASF Aktiengesellschaft (DE) | 1994-03-16 | — | — | EP | disclosed |
| US-5246931-A | Triazine-substituted cyclobutane derivatives; viricides; side effect reduction | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-09-21 | — | — | US | disclosed |
| US-5225402-A | Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| US-5153352-A | Viricides and antitumor agent | BRISTOL-MYERS SQUIBB COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
| US-5075488-A | Fungicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-12-24 | — | — | US | disclosed |
| EP-0128006-B1 | A SOIL-DISEASE-CONTROLLING AGENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-09-18 | — | — | EP | disclosed |
| US-5023260-A | Substituted uracils, processes for their preparation and their use against parasitic protozoa | BAYER AKTIENGESELLSCHAFT (DE) | 1991-06-11 | — | — | US | disclosed |
| US-4988703-A | Viricides of hydroxyethylcyclopropylguanine | ABBOTT LABORATORIES (US) | 1991-01-29 | — | — | US | disclosed |
| EP-0392298-A2 | Substituted uracils, process for their preparation and their use against parasiticidal protozoa | BAYER AG (DE) | 1990-10-17 | — | — | EP | disclosed |
| EP-0382185-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
| EP-0366059-A2 | Carbocyclic nucleoside analogs | BRISTOL-MYERS SQUIBB COMPANY (US) | 1990-05-02 | — | — | EP | disclosed |
| EP-0190857-B1 | QUINOLONE INOTROPIC AGENTS | Pfizer Limited (GB) | 1990-03-21 | — | — | EP | disclosed |
| US-4900839-A | SUBSTITUTED PHENYLPROPENAMIDES | PFIZER INC. (US) | 1990-02-13 | — | — | US | disclosed |
| US-4898872-A | Imidazo[4,5-b]pyridyl quinolone cardiac stimulants | PFIZER INC. (US) | 1990-02-06 | — | — | US | disclosed |
| EP-0330992-A2 | Novel cyclobutane Derivatives, processes for their preparation and pharmaceutical compositions comprising them | Nippon Kayaku Kabushiki Kaisha (JP) | 1989-09-06 | — | — | EP | disclosed |
| US-4837334-A | Precursors to quinolone inotropic agents | PFIZER INC. (US) | 1989-06-06 | — | — | US | disclosed |
| US-4835312-A | Production process of N-substituted amide compounds | MITSUI CHEMICALS, INCORPORATED (JP) | 1989-05-30 | — | — | US | disclosed |
| EP-0317188-A2 | Heteroaromatic enamide derivatives and their use as pesticides | ROUSSEL UCLAF (FR) | 1989-05-24 | — | — | EP | disclosed |
| EP-0290153-A1 | Heterobicyclic quinolone derivatives | Pfizer Limited (GB) | 1988-11-09 | — | — | EP | disclosed |
| EP-0104066-B1 | 5-HALOVINYL-2'-DEOXYURIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1988-08-10 | — | — | EP | disclosed |
| US-4740513-A | CARDIAC STIMULANTS | PFIZER INC. (US) | 1988-04-26 | — | — | US | disclosed |
| EP-0257918-A1 | Quinolone cardiac stimulants | Pfizer Limited (GB) | 1988-03-02 | — | — | EP | disclosed |
| US-4728653-A | CONGESTIVE HEART FAILURE | PFIZER INC. (US) | 1988-03-01 | — | — | US | disclosed |
| US-4728654-A | CONGESTIVE HEART FAILURE | PFIZER INC. (US) | 1988-03-01 | — | — | US | disclosed |
| US-4716170-A | 5-[1H-(5-membered-N-aromatic heteryl)-1-yl]-1,6-naphthyridin-2(1H)-ones and their cardiotonic use | STERLING DRUG INC. (US) | 1987-12-29 | — | — | US | disclosed |
| US-4710507-A | Quinolone inotropic agents | PFIZER INC. (US) | 1987-12-01 | — | — | US | disclosed |
| US-4709052-A | FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-11-24 | — | — | US | disclosed |
| US-4697021-A | 1,6-dihydro-6-oxo-3-pyridinecarbonitriles, intermediates for cardiotonic agents | STERLING DRUG INC. (US) | 1987-09-29 | — | — | US | disclosed |
| EP-0226357-A1 | Quinolone cardiac stimulants | Pfizer Limited (GB) | 1987-06-24 | — | — | EP | disclosed |
| US-4657915-A | INOTROPIC AGENTS | STERLING DRUG INC. (US) | 1987-04-14 | — | — | US | disclosed |
| US-4658044-A | Intermediates for uracil derivatives | GLAXO GROUP LIMITED (GB) | 1987-04-14 | — | — | US | disclosed |
| US-4634772-A | 2-[2-(di-lower-alkylamino)-1-propenyl]-6-methoxy-3-pyridinecarbonitriles, intermediates for cardiotonic agents | STERLING DRUG INC. (US) | 1987-01-06 | — | — | US | disclosed |
| EP-0190857-A2 | Quinolone inotropic agents | Pfizer Limited (GB) | 1986-08-13 | — | — | EP | disclosed |
| EP-0189853-A2 | 1,6-Naphthyridin-2(1H)-ones having cardiotonic activity and preparation | STERLING DRUG INC. (US) | 1986-08-06 | — | — | EP | disclosed |
| US-4578381-A | ANTIULCER AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-25 | — | — | US | disclosed |
| US-4564618-A | VIRICIDES | GLAXO GROUP LIMITED (GB) | 1986-01-14 | — | — | US | disclosed |
| EP-0166533-A1 | Quinolone inotropic agents | Pfizer Limited (GB) | 1986-01-02 | — | — | EP | disclosed |
| EP-0148623-A2 | Quinolone inotropic agents | Pfizer Limited (GB) | 1985-07-17 | — | — | EP | disclosed |
| EP-0128006-A2 | A soil-disease-controlling agent | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-12-12 | — | — | EP | disclosed |
| US-4487772-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| US-4468402-A | Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-28 | — | — | US | disclosed |
| US-4454130-A | CARDIOTONIC, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| US-4415572-A | CARDIOTONIC AND INOTROPIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-15 | — | — | US | disclosed |
| JP-S55143970-A | QUINOLINE DERIVATIVE, AND HERBICIDE CONTAINING SAID DERIVATIVE AS EFFECTIVE COMPONENT | NISSAN CHEM IND LTD | 1980-11-10 | — | — | JP | disclosed |
| US-4041038-A | ANESTHETICS | KYORIN PHARMACEUTICAL CO., LTD. (JA) | 1977-08-09 | — | — | US | disclosed |
| US-4041038-A | ANESTHETICS | KYORIN PHARMACEUTICAL CO., LTD. (JA) | 1977-08-09 | — | — | US | disclosed |